07:10 AM EST, 11/25/2024 (MT Newswires) -- Merck ( MRK ) said Monday its experimental drug Winrevair, for pulmonary arterial hypertension, met primary endpoint in a phase 3 study.

In the study, patients treated with Winrevair showed a statistically significant and clinically meaningful reduction in risk of morbidity or mortality compared to placebo.

The company said after the data from the study, an independent committee recommended ending the trial early, with participants offered access to Winrevair through an open-label extension study.